Regeneron Pharmaceuticals PT Raised to $383.00 (REGN)
Equities research analysts at Goldman Sachs increased their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $353.00 to $383.00 in a research note issued to investors on Thursday, Analyst RN reports. Goldman Sachs’ price objective indicates a potential upside of 19.65% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Wednesday. They set a “buy” rating and a $387.00 price target on the stock. Separately, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals to $410.00 in a research note on Tuesday. Finally, analysts at TheStreet reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $314.97.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 320.38 on Thursday. Regeneron Pharmaceuticals has a 52 week low of $154.16 and a 52 week high of $331.64. The stock’s 50-day moving average is $285. and its 200-day moving average is $280.. The company has a market cap of $31.469 billion and a P/E ratio of 46.49.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 11th. The company reported $2.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the prior year, the company posted $1.47 earnings per share. The company’s quarterly revenue was up 47.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $6.21 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Alfred G. Gilman unloaded 5,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $320.00, for a total transaction of $1,600,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.